Interview: N4 Pharma’s CEO Nigel Theobald discusses strategic moves and future of pharma

2024-05-09T09:45:23+01:00May 9th, 2024|Article, Blog, News|

In an interview with World Pharma Today, Nigel Theobald, CEO N4 Pharma, answers questions about the company’s latest news and future plans. Key highlights from the discussion include: Acquisition: our recent acquisition of Nanogenics Limited and how it enhances our product offerings in gene therapy. Collaborative partnerships: our partnerships [...]

Article: A drug delivery strategy emerges that has the potential to transform cancer therapy

2024-03-07T12:06:54+00:00March 7th, 2024|Article, Blog, News|

In our latest article, we look at how the dual delivery of siRNA – via delivery systems such as Nuvec® – holds the potential to pave the way for a new era of improved efficiency in cancer treatment. Nuvec® has the potential to offer a solution that reduces the [...]

Article: Could new-generation silica nanoparticles be the next big thing in siRNA delivery systems for cancer treatment? 

2023-05-10T09:49:58+01:00May 4th, 2023|Article, Blog, News|

In our latest article, we look at how Nuvec® offers an alternative to current drug delivery approaches for small interfering RNA (siRNA). Not only is Nuvec® particularly suited to chemical modification, allowing the addition of target specific ligands to receptors on cancer cells, but it may offer the convenience of [...]

Go to Top